Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interpore strikes development deal with Quantic:

This article was originally published in Clinica

Executive Summary

Bone graft developer Interpore has agreed a licence and development deal with Quantic Biomedical, based in San Rafael, California. It gives Interpore rights to a technology that produces super-concentrated tissue growth factors derived from a patient's own blood. The two companies intend to develop a bone and cartilage repair product combining Interpore's Pro Osteon bone graft substitute with Quantic's autologous growth factor concentrates.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel